These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 30403305)

  • 1. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM; Pai MP; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological considerations for the proper clinical use of aminoglycosides.
    Pagkalis S; Mantadakis E; Mavros MN; Ammari C; Falagas ME
    Drugs; 2011 Dec; 71(17):2277-94. PubMed ID: 22085385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.
    Owens RC; Shorr AF
    Am J Health Syst Pharm; 2009 Jun; 66(12 Suppl 4):S23-30. PubMed ID: 19502225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How predictive is PK/PD for antibacterial agents?
    Frimodt-Møller N
    Int J Antimicrob Agents; 2002 Apr; 19(4):333-9. PubMed ID: 11978504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
    Mueller EW; Boucher BA
    Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimisation of antimicrobial dosing based on pharmacokinetic and pharmacodynamic principles.
    Hoo GSR; Liew YX; Kwa AL
    Indian J Med Microbiol; 2017; 35(3):340-346. PubMed ID: 29063877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing use of aminoglycosides in the critically ill.
    Rea RS; Capitano B
    Semin Respir Crit Care Med; 2007 Dec; 28(6):596-603. PubMed ID: 18095223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
    Drusano GL; Preston SL; Hardalo C; Hare R; Banfield C; Andes D; Vesga O; Craig WA
    Antimicrob Agents Chemother; 2001 Jan; 45(1):13-22. PubMed ID: 11120938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles.
    Klutman NE
    Pharm Pract Manag Q; 1996 Jul; 16(2):9-12. PubMed ID: 10161616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.
    Arnold A; Brouse SD; Pitcher WD; Hall RG
    J Intensive Care Med; 2010 Sep; 25(5):259-70. PubMed ID: 20622257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
    Zavascki AP; Klee BO; Bulitta JB
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
    Kitamura Y; Yoshida K; Kusama M; Sugiyama Y
    Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.
    Kashuba AD; Nafziger AN; Drusano GL; Bertino JS
    Antimicrob Agents Chemother; 1999 Mar; 43(3):623-9. PubMed ID: 10049277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.